import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'uae-neurology-cns-market-report';

/**
 * Curated copy for the UAE neurology & CNS programmatic report.
 * Market sizing: BioNixus market analysis, 2026 (aligned with factRegistry: ~USD 152M 2026 → ~USD 248M 2030, ~14.9% CAGR).
 * Detail: MOHAP/DHA/DOH access, insurer prior authorization, MS DMTs, CGRP migraine, mental-health expansion; epidemiology cited as published ranges.
 */
type OverrideCopy = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const UAE_NEUROLOGY_CNS_COPY: OverrideCopy = {
  slug: SLUG,
  title: 'UAE Neurology & CNS Market Report 2026',
  metaTitle: 'UAE Neurology & CNS Market Report 2026 | BioNixus',
  metaDescription:
    'UAE neurology & CNS market ~USD 152M in 2026 (BioNixus analysis), ~14.9% CAGR: MOHAP/DHA/DOH access, insurer prior authorization for MS DMTs and CGRP migraine agents, epilepsy, mental-health growth—decision-ready Gulf intelligence.',
  heroLead:
    'This briefing reads UAE neurology and CNS through its insurance logic: high-cost MS disease-modifying therapies and CGRP migraine agents gated by emirate insurer prior authorization, a premium private neurology sector, a rising Gulf MS burden, and a fast-growing mental-health segment in an affluent, expatriate-rich population.',
  summaryPara1:
    'Neurology and CNS in the UAE pairs a high-volume base (epilepsy, migraine, stroke, psychiatry) with a high-value, insurance-funded frontier of multiple sclerosis disease-modifying therapies and CGRP migraine agents. BioNixus sizes the market at roughly USD 152 million in 2026, reaching about USD 248 million by 2030 (14.9% CAGR). MS is a key driver: the Gulf carries a rising MS burden, and high-cost DMTs concentrate at premium private and government neurology centres, where access depends on insurer prior authorization rather than the MOHAP label. CGRP monoclonal antibodies are expanding migraine prophylaxis, and mental-health demand is growing in a young, affluent population. Access turns on the three-authority landscape (MOHAP, DHA, DOH) and emirate-specific payer policy. Sizing reflects BioNixus market analysis, 2026.',
  summaryPara2:
    'Use this report with the [UAE healthcare market report](/uae-healthcare-market-report) for macro context, the [UAE rare diseases market report](/market-reports/uae-rare-diseases-market-report) for the neuromuscular/SMA overlap, the [GCC neurology & CNS market report](/market-reports/gcc-neurology-cns-market-report) for Gulf-wide benchmarking, the [Saudi Arabia neurology & CNS market report](/market-reports/saudi-arabia-neurology-cns-market-report) for the larger neighbouring market, [neurology & CNS therapy research](/healthcare-market-research/therapy/neurology-cns) for programme design, and the [healthcare market research hub](/healthcare-market-research) to scope bilingual fieldwork.',
  marketAccessNotes:
    'Mandatory-insurance prior authorization for high-cost MS DMTs (ocrelizumab, natalizumab, cladribine, S1P modulators) varying by emirate and payer (Thiqa, Daman, Dubai plans); CGRP monoclonal antibodies (erenumab, galcanezumab, fremanezumab) entering migraine prophylaxis via specialist prior authorization; MOHAP registration plus DHA/DOH facility requirements; premium private neurology and headache centres anchoring high-value initiation; mental-health expansion and de-stigmatisation widening psychiatric prescribing; expatriate continuity-of-care and prior-treatment documentation shaping MS DMT eligibility; MRI and specialist-neurologist access gating diagnosis',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat UAE neurology as a payer-segmented, centre-concentrated market layered on a young, mobile population. The same MS DMT can clear under one Abu Dhabi insurer and stall under a Dubai plan, while premium private centres run different access logic than government hospitals. We pair bilingual neurologist and psychiatrist quantitative work with insurer and payer-medical-director depth, and we capture the expatriate dynamic—prior MS or migraine treatment from abroad that prior-authorization rules may not recognise, and continuity gaps when patients change insurers. Operational realities matter: MRI and specialist access for MS diagnosis, headache-clinic capacity for CGRP prophylaxis, and a mental-health segment expanding from a low base. KOL maps follow real MS-clinic, headache-clinic, and psychiatry influence across the flagship institutions.',
  commercialOutlookParagraph:
    'The outlook to 2030 favours teams that win insurer medical policy emirate by emirate while engaging the premium private neurology ecosystem. MS DMTs drive value as the Gulf MS burden rises and high-cost therapy concentrates at specialist centres; CGRP agents expand migraine prophylaxis; and mental-health prescribing grows from a low base in an affluent, young population. Manufacturers should plan emirate-specific prior-authorization strategies, MS and headache-clinic support, documentation that handles expatriate prior-treatment history, and diagnostic enablement. Because a small set of insurers and premium centres shapes most high-value volume, share assumptions should be stress-tested by emirate, payer, and centre before regional revenue targets are locked.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for sizing and CAGR bands with structured desk review of MOHAP, DHA, DOH, and insurer public guidance, plus primary modules—neurologist and psychiatrist adoption surveys, insurer and payer medical-policy interviews, and MS and migraine pathway mapping where data is available. Epidemiology references use published UAE and regional neurological burden ranges (including rising Gulf MS prevalence) as planning inputs, not patient-level forecasts. Because insurer medical policies, prior-authorization criteria, and diagnostic capacity change on short cycles, access statements should be revalidated before launch decisions. Outputs are built for market access, medical affairs, and commercial leadership and do not constitute regulatory or clinical advice.',
  faqs: [
    {
      question: 'How large is the UAE neurology and CNS market in 2026?',
      answer:
        'BioNixus market analysis sizes the UAE neurology and CNS market at roughly USD 152 million in 2026, advancing toward about USD 248 million by 2030 at roughly 14.9% CAGR. A high-volume base — epilepsy, migraine, stroke, and psychiatry — underpins prescribing volume, but the value growth comes from high-cost multiple sclerosis disease-modifying therapies and CGRP migraine agents, supported by a premium private neurology sector and a mental-health segment expanding from a low base. Because the high-value therapies are insurance-gated and centre-concentrated, the realistic opportunity tracks payer policy and specialist capacity rather than raw prevalence. BioNixus treats the figure as a planning band tied to insurer access and diagnostic infrastructure. Use the GCC neurology and CNS report for Gulf-wide context, the UAE rare diseases report for the neuromuscular overlap, and the UAE healthcare market report for macro sizing.',
    },
    {
      question: 'How do MS disease-modifying therapies gain access in the UAE?',
      answer:
        'High-cost MS disease-modifying therapies — ocrelizumab, natalizumab, cladribine, and the S1P receptor modulators — are largely insurance-funded, so access depends on emirate-specific insurer prior authorization rather than on the MOHAP label alone. Initiation concentrates at premium private and government neurology centres, and MRI availability and specialist-neurologist access gate the diagnosis that precedes any prescription. The expatriate dimension is significant: patients frequently arrive already established on a DMT abroad, which complicates prior-authorization rules that expect a documented local treatment history and can interrupt continuity when a patient changes insurer. BioNixus maps these payer and centre pathways directly with neurologists and insurer medical directors, so teams can plan emirate-specific access, anticipate where prior-authorization friction will delay switching or initiation, and identify the centres that actually drive DMT volume.',
    },
    {
      question: 'How is the migraine and CGRP market developing in the UAE?',
      answer:
        'CGRP monoclonal antibodies — erenumab, galcanezumab, and fremanezumab — are expanding migraine prophylaxis through specialist and headache-clinic channels, but they are subject to insurer prior authorization because of their cost relative to older oral prophylactics. As a result, adoption is paced far more by specialist referral and payer policy than by the large underlying migraine prevalence, and funded use lags well behind clinical eligibility. As dedicated headache clinics grow within the premium private sector, the prophylaxis opportunity widens, but it remains concentrated among neurologists willing to navigate prior authorization. BioNixus tracks neurologist adoption alongside payer criteria specifically to separate prescribing intent from funded use, because in the UAE the gap between the two is wide and is the most common reason CGRP forecasts built on prevalence overshoot.',
    },
    {
      question: 'How does insurance shape CNS access across the UAE?',
      answer:
        'Most CNS prescribing in the UAE is insurance-funded, and the rules differ across MOHAP, DHA, and DOH plans rather than following a single national standard. High-cost MS and CGRP therapies face prior-authorization criteria that vary by emirate and by payer, while the epilepsy and psychiatry base depends more on formulary placement and private-payer cost control. A large, mobile expatriate population adds continuity-of-care and prior-treatment-documentation considerations, particularly for patients who change insurers mid-therapy or arrive already treated abroad. BioNixus recommends mapping MOHAP approval, DHA and DOH facility access, and insurer prior-authorization rules per emirate rather than assuming a single national pathway, and revalidating those rules before launch, because CNS medical policies — especially for high-cost MS and migraine agents — are revised on short cycles across the three authorities.',
    },
    {
      question: 'Which neurology and CNS classes are growing fastest in the UAE?',
      answer:
        'MS disease-modifying therapies are a major value driver given a rising Gulf MS burden and high per-patient cost, and they anchor most of the market’s value growth. CGRP agents are the fastest-growing migraine segment, while neuromuscular therapies, including spinal muscular atrophy agents, overlap with the rare-disease pathway and its named-patient and high-cost-funding routes. Mental-health prescribing is growing from a low base as de-stigmatisation and access widen in a young, affluent population. The epilepsy and stroke base remains steady but competes mainly on formulary placement and cost rather than novelty. BioNixus tracks these class dynamics so teams can prioritise the segments where rising burden, specialist readiness, and insurer willingness to fund are converging rather than spreading effort across the whole CNS category.',
    },
    {
      question: 'How does BioNixus help neurology and CNS teams win in the UAE?',
      answer:
        'BioNixus designs bilingual (Arabic–English) UAE neurology and CNS programmes: neurologist and psychiatrist adoption studies, insurer and payer medical-policy interviews, emirate-level prior-authorization mapping for MS and CGRP therapies across MOHAP, DHA, and DOH, and KOL mapping tied to real MS-clinic, headache-clinic, and psychiatry influence. Deliverables align to launch, high-cost-access, or category-expansion milestones and connect UAE findings to GCC and global benchmarks only when a comparator truly informs governance. Typical outputs include emirate and payer archetypes, access-risk maps, diagnostic-capacity analysis, and committee-ready executive summaries. We separate the insured MS and CGRP value pool from the formulary-driven epilepsy and psychiatry base, since the access levers differ sharply between them. Begin from the healthcare market research hub or request a scoped briefing through the contact page.',
    },
  ],
};
